HCC
GSK icon

Hirtle Callaghan & Co’s GSK GSK Stock Holding History

Hirtle Callaghan & Co’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-802
Closed -$43K – 169
2014
Q4 		$43K Hold
802
– – 0.01% 310
2014
Q3 		$47K Sell
802
-21
-3% -$1.29K 0.01% 313
2014
Q2 		$56K Hold
823
– – 0.01% 343
2014
Q1 		$56K Hold
823
– – 0.01% 335
2013
Q4 		$56K Buy
823
+21
+3% +$1.36K 0.01% 320
2013
Q3 		$51K Buy
+802
New +$51.6K 0.01% 339

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hirtle Callaghan & Co's GSK Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of GSK (GSK) in Q1 2015, closing a stake of 802 shares — an estimated $43K sold.

Hirtle Callaghan & Co first reported a position in GSK in Q3 2013 and held it in 6 quarters. The position peaked at $56K in Q2 2014. 740 funds tracked by Wall St. Rank hold GSK as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining GSK position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 802 GSK shares in Q1 2015, an estimated $43K.
  • Hirtle Callaghan & Co first reported a position in GSK in Q3 2013 and held it in 6 quarters.
  • Hirtle Callaghan & Co's GSK position peaked at $56K in Q2 2014.
  • 740 funds tracked by Wall St. Rank held GSK as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.